3.93

1.55% 0.06

After Hours: 3.91 -0.02 -0.51%

Precigen Inc (PGEN)

Overview News Price History Option Chain Financials Discussions Forecast

Precigen Inc stock is traded at $3.93, with a volume of 5.73M. It is up +1.55% in the last 24 hours and up +3.69% over the past month. Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.

Previous Close:

$3.87

Open:

$3.81

24h Volume:

5.73M

Relative Volume:

1.22

Market Cap:

$1.39B

Revenue:

$9.68M

Net Income/Loss:

$-250.64M

P/E Ratio:

-2.8075

EPS:

-1.3998

Net Cash Flow:

$-89.83M

1W Performance:

+26.77%

1M Performance:

+3.69%

6M Performance:

+17.66%

1Y Performance:

+173.87%

1-Day Range:

$3.78

$4.06

1-Week Range:

$3.22

$4.275

52-Week Range:

$1.11

$5.465

Precigen Inc Stock (PGEN) Company Profile

Name

Precigen Inc

Sector

Healthcare (1116)

Industry

Biotechnology (621)

Phone

301-556-9900

Address

20374 SENECA MEADOWS PARKWAY, GERMANTOWN, MD

Employee

Twitter

@precigen

Next Earnings Date

2026-03-25

Latest SEC Filings

PGEN's Discussions on Twitter

Compare PGEN vs VRTX, REGN, ARGX, ALNY, INSM

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PGEN Precigen Inc	3.93	1.37B	9.68M	-250.64M	-89.83M	-1.3998
VRTX Vertex Pharmaceuticals Inc	447.26	113.44B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	777.25	81.68B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	743.12	45.32B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	328.73	43.88B	3.71B	313.75M	465.38M	2.2571
INSM Insmed Inc	164.86	35.25B	606.42M	-1.28B	-997.58M	-6.403

Precigen Inc Stock (PGEN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-15-25	Upgrade	JP Morgan	Underweight → Neutral
Mar-22-24	Downgrade	JP Morgan	Neutral → Underweight
May-23-23	Initiated	JP Morgan	Neutral
Nov-18-22	Initiated	Cantor Fitzgerald	Overweight
Feb-25-21	Initiated	Stifel	Buy
Feb-22-21	Initiated	Wells Fargo	Overweight
Feb-18-21	Initiated	B. Riley Securities	Buy
May-08-20	Initiated	H.C. Wainwright	Buy

View All

Precigen Inc Stock (PGEN) Latest News

06:26 AM

PGEN PE Ratio & Valuation, Is PGEN Overvalued - intellectia.ai

06:26 AM

04:29 AM

Precigen, Inc. (NASDAQ:PGEN) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat

04:29 AM

Mar 31, 2026

Randal J. Kirk (PGEN) entities sell 4.8M shares, still hold over one-third stake - Stock Titan

Mar 31, 2026

Precigen Details Papzimeos Commercial Launch, Hub Growth and J-Code Catalyst at H.C. Wainwright Chat - MarketBeat

Mar 31, 2026

Precigen (NASDAQ:PGEN) Stock Price Up 11.2%What's Next? - marketbeat.com

Mar 31, 2026

These analysts boost their forecasts on Precigen following Q4 results - MSN

Mar 31, 2026

Mar 30, 2026

[144] PRECIGEN, INC. SEC Filing - Stock Titan

Mar 30, 2026

Precigen (NASDAQ:PGEN) Shares Down 9%Time to Sell? - MarketBeat

Mar 30, 2026

Precigen to Participate in a Fireside Chat with H.C. Wainwright on March 31 - Bitget

Mar 30, 2026

4,772,781 Precigen (PGEN) shares sold by entities tied to Randal Kirk - Stock Titan

Mar 30, 2026

HC Wainwright Estimates Precigen's Q1 Earnings (NASDAQ:PGEN) - MarketBeat

Mar 30, 2026

Mar 28, 2026

Precigen (PGEN) Is Up 11.9% After PAPZIMEOS’ Launch Shifts Focus Toward Commercial Revenue Model - simplywall.st

Mar 28, 2026